
==== Front
Cancer Immunol Immunother
Cancer Immunol Immunother
Cancer Immunology, Immunotherapy : CII
0340-7004
1432-0851
Springer Berlin Heidelberg Berlin/Heidelberg

3834
10.1007/s00262-024-03834-y
Research
Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis
Chen Ruxuan 1
Shi Yujie 1
Fang Nan 2
Shao Chi 1
http://orcid.org/0000-0001-7184-0005
Huang Hui pumchhh@126.com

1
Pan Ruili 1
Xu Yan 1
Wang Mengqi 3
Liu Xiangning 3
Xu Kai 4
Zhu Rui 5
Wang Mengzhao 1
1 grid.506261.6 0000 0001 0706 7839 Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, #1 Shuaifuyuan Street, Dongcheng District, Beijing, 100730 China
2 https://ror.org/02drdmm93 grid.506261.6 0000 0001 0706 7839 State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, #1 Xian Nong Tan Street, Beijing, 100050 China
3 grid.506261.6 0000 0001 0706 7839 Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, #1 Shuaifuyuan Street, Dongcheng District, Beijing, 100730 China
4 grid.506261.6 0000 0001 0706 7839 Department of Radiology, Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, #1 Shuaifuyuan Street, Dongcheng District, PekingBeijing, 100730 China
5 grid.506261.6 0000 0001 0706 7839 Department of Medical Records, Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, #1 Shuaifuyuan Street, Dongcheng District, PekingBeijing, 100730 China
13 9 2024
13 9 2024
11 2024
73 11 2357 6 2024
6 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Checkpoint inhibitor pneumonitis (CIP) is a relatively uncommon but potentially life-threatening immune-related adverse event (irAE). Lung biopsies have not been commonly performed for CIP patients. Bronchoalveolar lavage fluid (BALF) analysis is a useful diagnostic approach for interstitial lung disease. However, BALF features were inconsistent across different studies.

Methods

We retrospectively reviewed the medical records of 154 patients with pathologically confirmed malignancies and suffering from CIPs between July 2018 and December 2022. Patients who had bronchoalveolar lavage (BAL) data available were enrolled in our study. Patient clinical, laboratory, radiological and follow-up data were reviewed and analyzed.

Results

The BALF differential cell count and lymphocyte subset analysis were performed for 42 CIP patients. There were 32 males (76.2%). The mean age at diagnosis of CIP was 62.0 ± 10.4 (range: 31–78) years. The median time to onset of CIP was 98.5 days after the start of immunotherapy. There were 18 patients (42.9%) with low-grade CIPs and 24 patients (57.1%) with high-grade CIPs. The mean lymphocyte percentage was 36.7 ± 22.5%. There were 34 (81%) CIP patients with a lymphocytic cellular pattern. The median ratio of CD3+CD4+/CD3+CD8+ lymphocytes was 0.5 (0.3, 1.0). The ratio was less than 1.0 for 31 CIP patients (73.8%). However, there was no significant difference in the BALF features between patients with low-grade CIPs and those with high-grade CIPs.

Conclusions

The CD3+CD8+ lymphocytosis pattern was the main inflammatory profile in the BALF of CIP patients in this cohort. Targeting CD3+CD8+ lymphocytes might be a treatment option for CIPs.

Keywords

Checkpoint inhibitor pneumonitis
Bronchoalveolar lavage fluid
Lymphocyte subset analysis
Immune-related adverse event
National High Level Hospital Clinical Research Funding2022-PUMCH-C-069 2022-PUMCH-A-009 2022-PUMCH-C-054 Huang Hui Pan Ruili Wang Mengzhao issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcIntroduction

Anti-programmed cell death 1 (PD-1)/anti-PD ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) improve the prognosis of patients with various malignancies. However, the occurrence of immune-related adverse events (irAEs) cannot be ignored. Although most irAEs are managable, some are fatal, e.g., checkpoint inhibitor pneumonitis and myocarditis [1–4]. The overactivation of T cells that recognize self-proteins or commensal microorganisms is presumed to be the probable pathogenesis of irAEs [5, 6]. Cluster of differentiation 8-positive (CD8+) lymphocyte infiltration in irAE-targeted tissues and/or organs was shown in patients with checkpoint inhibitor-induced colitis and myocarditis [6–8]. However, the features of T-cell subsets associated with checkpoint inhibitor pneumonitis (CIP) were not consistent across different studies. Bukhari et al. analyzed peripheral blood T-cell subtypes and reported that different populations of T cells were associated with pulmonary radiographical-immunological correlation [5]. Suresh et al. reported that bronchoalveolar lavage fluid (BALF) analysis of CIP patients revealed lymphocytosis and ﻿predominantly CD4+ T cells [9]. Compared with the control group (cancer patients who had received immunotherapy and did not develop CIP), BALF CD8+ T cell percentage of live cells was also higher in the CIP group, but failed to show statistical significance. And the median percentages of CD4+ T cells and CD8+ T cells were close (both were around 10% of live cells). However, the proportion of CD8+ cells among T cells was significantly or tended to be higher for CIP than for the other types of ILD in Suzuki’s CIP study [10].

Lung biopsies are not commonly performed for CIP patients [11], and BALF analysis is a useful diagnostic procedure for the differentiation of interstitial lung diseases (ILDs), infectious pulmonary diseases or pulmonary malignancies, especially for fragile patients and/or ﻿patients at high risk for severe complications after percutaneous or surgical lung biopsy [12, 13]. Elucidation of the characteristics of inflammatory cells in BALF might help us to understand the underlying pathophysiological process of CIPs. To date, the exact etiology and pathogenesis of CIP have not been determined. However, detailed studies on the BALF characteristics of CIP patients have rarely been reported. Therefore, we conducted this retrospective study to describe the inflammatory cellular patterns and T lymphocyte subset features in the BALF of CIP patients.

Patients and methods

Patients

There were 154 patients with pathology-confirmed malignancies suffering from CIPs after ICI therapy who were admitted to Peking Union Medical College Hospital from July 2018 to December 2022. Among them, forty-nine patients underwent bronchoalveolar lavage (BAL). Finally, 42 CIP patients with intact BALF analysis data were enrolled in our study (Fig. 1 shows the study flowchart). Follow-up information was obtained through outpatient follow-up records or telephone conversations with patients or their families. There were 4 kinds of outcomes in CIP patients, namely, cured, improved, deteriorated or dead.Fig. 1 Study flowchart

Definitions

The diagnostic criteria for CIP were as follows [14]: 1) new onset or exaggeration of respiratory manifestations, especially dry cough, dyspnea, or a decrease in oxygen saturation (easily measured by a finger pulse oxygen saturation detector); 2) a positive history of ﻿immunotherapy with anti-PD-1/PD-L1; 3) new onset of lung shadows characterized by computed tomography (CT) features of ILD [15]; and 4) exclusion of infectious pulmonary diseases, primary lung cancer progression and/or metastatic malignancies, pulmonary edema, pulmonary hemorrhage, and other mimics.

The severity of CIPs was classified by the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) [16] when they were diagnosed with CIP: asymptomatic/mild (grade 1), moderate (grade 2), severe (grade 3), life-threatening (grade 4), or death (grade 5). In our study, patients with grade 1 or grade 2 CIPs were defined as low-grade CIPs, and patients with grade 3, grade 4 or grade 5 CIPs were defined as high-grade CIPs.

Serum cytokine levels were measured using IMMULITE 1000 Automated Immunoassay Analyzer (Siemens).

For BALF analyses, the following tests were performed: differential cell count, lymphocyte subset analysis, microbiological and virological tests, and malignant cell cytological examination. A minimal volume of 10 ml (generally 10 to 20 ml) of a pooled BALF sample was sent for BALF cellular analysis for each patient. The differential cell counts included macrophage, lymphocyte, neutrophil, and eosinophil cell counts.

T lymphocyte subset analysis of BALF was performed by flow cytometry. BALF samples were passed through a mesh filter to remove debris and then centrifuged to isolate cells. Cells were stained with a panel of flow antibodies included CD45-FITC, CD3-APC-A750, CD4-PC5.5, and CD8-APC-A700 (Beckman Coulter). Samples were analyzed using the Navios flow cytometry system.

Statistical analysis

The data were analyzed using the SAS version 9.4 software package (SAS Institute, Inc., SAS Campus Drive, Cary, North Carolina 27,513, USA). The GraphPad Prism 6XML project (GraphPad Software, San Diego, CA, USA) was used for graphing. Continuous variables are presented as means ± standard deviations (SD) for data with normal distribution, and as median and interquartile range (IQR) for non-normally distributed data. Normal distribution of continuous data was assessed with the Kolmogorov–Smirnov test. Categorical variables are expressed as frequencies and percentages. The t test or rank-sum test was used for continuous variables, and the chi-square test was used for categorical variables. A two-tailed P < 0.05 was considered to indicate statistical significance.

Results

Clinical characteristics of CIP patients

Forty-two CIP patients with complete BALF analysis data were enrolled in our study. There were 32 males (76.2%) and 10 females (23.8%). When they suffered from CIPs, they were 62.0 ± 10.4 (range: 31–78) years old. Most of them were older than 60 years (29 patients, 69.0%) and had a smoking history [26 patients/61.9%, 30 (20, 50) pack-year]. However, only 11 patients (26.2%) had emphysema. The range of Eastern Cooperative Oncology Group (ECOG) score was 0–2. Most of them were diagnosed with lung cancer (36 patients, 85.7%). There were 3 patients with esophageal squamous cell cancer, 1 patient with hepatic cell cancer, 1 patient with gastric signet ring cell cancer and 1 patient with pericardial malignant mesothelioma. The median time to onset of CIP was 98.5 days (3.28 months) after the first dose of ICIs.

According to the CTCAE, there were 2 patients (4.8%) with grade 1 CIPs, 16 patients (38.1%) with grade 2 CIPs, 20 patients (47.6%) with grade 3 CIPs and 4 patients (9.5%) with grade 4 CIPs. Therefore, there were 18 patients (42.9%) in the low-grade CIP group and 24 patients (57.1%) in the high-grade CIP group. The clinical and radiological characteristics of the patients in the low-grade CIP group and high-grade CIP group are listed in Table 1. There were no significant differences in age, male patient percentage or smoking history between patients with high-grade CIPs and those with low-grade CIPs (64.5 years vs. 61.5 years, P = 0.18; 79.2% vs. 72.2%, P = 0.60; 66.7% vs. 58.8%, P = 0.61). Table 1 Clinical and radiological characteristics between low-grade and high-grade CIPs

Characteristics	High-grade CIP (n = 24)	Low-grade CIP (n = 18)	χ2 or t value	P value	
Age (years)*	64.5 (61.3, 70.5)	61.5 (48.3, 68.0)	 − 1.32	0.18	
Gender (male%)	79.2%	72.2%	0.27	0.60	
Smoking history(n/%)**	16/66.7%	10/58.8%	0.26	0.61	
Lung cancer(n/%)	18/75%	18/100%	7.46	0.01	
ECOG before ICIs therapy (n/%)	
0	13/54.2%	12/66.7%			
1	10/41.7%	5/27.8%	 1.92	0.38	
2	1/4.2%	1/5.6%			
Preexisting ILDs(n/%)	4/16.7%	1/6.3%	1.03	0.31	
Non-surgical treatment(n/%)	
Thoracic radiotherapy (n/%)	9/37.5%	7/38.9%	0.01	0.93	
Molecular targeted therapy	4/4.2%	5/27.8%	4.87	0.03	
Chemotherapy	19/79.2%	15/83.3%	0.12	0.59	
ICIs as first line(n/%)	14/58.3%	9/50%	0.21	0.65	
Onset of CIP (days)***	69.5 (43.5, 207.5)	157 (75.2, 272.5)	 − 1.41	0.16	
Fever	11/45.8%	6/33.3%	0.67	0.41	
HRCT pattern					
UIP pattern	0	0			
NSIP pattern	9/37.5%	6/33.3%			
OP pattern	10/41.7%	11/61.1%	2.31	0.13	
Overlap pattern	4/16.7%	0			
Unclassified pattern	1/4.2%	1/5.6%			
Emphysema	9/37.5%	2/11.1%	4.0	0.046	
With other irAEs(n/%)	6/25%	5/27.8%	0.04	0.84	
CIP: checkpoint inhibitor pneumonitis, ECOG: Eastern Cooperative Oncology Group performance score, ICI: immune checkpoint inhibitor, ILD: interstitial lung disease, irAE: ﻿immune-related adverse event, NSIP: nonspecific interstitial pneumonia, OP: organizing pneumonia, UIP: usual interstitial pneumonia

*at the diagnosis of CIP, **: both current and former smokers, ***: the time interval from the first dose of ICIs to the onset of CIPs

Lung cancer was more common in patients with low-grade CIPs than in patients with high-grade CIPs (100% vs. 75%, P = 0.01), however, there was no significant difference in preexisting ILDs between these two groups (58.3% vs. 50%, P = 0.65). During ICI treatment, patients with low-grade CIPs were more commonly treated with molecular targeted therapy than patients with high-grade CIPs (27.8% vs. 4.2%, P = 0.03). There was no significant difference in the prevalence of thoracic radiotherapy or chemotherapy combined with ICI treatment between patients with high-grade CIPs and those with low-grade CIPs (37.5% vs. 38.9%, P = 0.93; 79.2% vs. 83.3%, P = 0.59, respectively). Both organizing pneumonia (OP) and nonspecific interstitial pneumonia (NSIP) high-resolution CT (HRCT) patterns were the main radiological patterns for patients with high-grade and low-grade CIPs (41.7% vs. 61.1%, 37.5% vs. 33.3%, respectively; P = 0.13). Emphysema was more common on HRCT of patients with high-grade CIPs (37.5% vs. 11.1%, P = 0.046). Approximately 1/4 of the CIP patients in our study suffered from other irAEs concomitantly: 25% in the high-grade CIP group versus. 27.8% in the low-grade CIP group.

BALF cellular analysis

In our CIP cohort, the BALF differential cell counts are shown in Fig. 2, and the lymphocyte subset analysis is shown in Fig. 3. The BALF total cell count was 17.1 (11.9, 31.0) × 106/L, the macrophage percentage was 47.7 ± 23.9% of total live cells, the lymphocyte percentage was 36.7 ± 22.5%, the neutrophil percentage was 5.3% (2%, 16.4%), and the eosinophil percentage was 1% (0, 2.5%). A differential BALF cell count with greater than 15% lymphocytes was defined as a lymphocytic cellular pattern. Thirty-four CIP patients (81%) exhibited a lymphocytic cellular pattern.Fig. 2 The bronchoalveolar lavage fluid cell differential count results of checkpoint inhibitor pneumonitis (CIP) patients. A Total cell count of BALF. Data for individual patients as well as the median and interquartile range are shown. B Cell percentages of different cells. Data are presented using means and standard deviations

Fig. 3 The bronchoalveolar lavage fluid lymphocyte subset analysis results of checkpoint inhibitor pneumonitis (CIP) patients. A Lymphocyte percentage of CD3+, CD3+CD4+, and CD3+CD8+ cells. Data are presented using means and standard deviations. B CD4 + /CD8 + ratio. Data for individual patients as well as the median and interquartile range are shown. C Representative flow cytometric analysis of T cells in BALF

As for the BALF lymphocyte subset analysis, the median percentage of CD3+ lymphocytes was 96.7% (94.3%, 97.6%) of total lymphocytes, the mean percentage of CD3+CD4+ lymphocytes was 31.0 ± 16.9% of total lymphocytes, the mean percentage of CD3+CD8+ lymphocytes was 58.8 ± 19.4% of total lymphocytes, and the median ratio of CD3+CD4+/CD3+CD8+ lymphocytes was 0.5 (0.3, 1.0). There were 31 CIP patients (73.8%) with a CD3+CD4+/CD3+CD8+ lymphocyte ratio less than 1; in other words, CD8+ lymphocytes were the main group of BALF T lymphocytes.

The BALF differential cell counts and lymphocyte subset analyses between high-grade and low-grade CIPs are shown in Table 2, and there was no significant difference between the two groups. There were 19 patients (79.2%) with high-grade CIP and 15 patients (83.3%) with low-grade CIP manifesting a lymphocytic cellular pattern. There were 18 patients (75%) with high-grade CIP and 13 patients (72.2%) with low-grade CIP having a CD3+CD4+/CD3+CD8+ lymphocyte ratio less than 1.0. Table 2 Bronchoalveolar lavage fluid analysis between high-grade and low-grade checkpoint inhibitor pneumonitis (CIP) groups

Characteristics	High-grade CIP (n = 24)	Low-grade CIP (n = 18)	χ2 or t value	P value	
Cell differential count	
 Total cell count (× 106/L)	16.2(12.4, 31.7)	18.5(8.7, 30.7)	 − 0.23	0.82	
 Macrophages percentage (%)	46.6 ± 24.4	49.3 ± 24.6	0.53	0.59	
 Lymphocytes percentage (%)	37.6 ± 23.8	35.4 ± 21.2	 − 0.33	0.74	
 Neutrophils percentage (%)	5.3(1.6, 16.4)	5(1.7, 19)	 − 0.06	0.95	
 Eosinophils percentage (%)	0.75(0, 2)	1.0(0.4, 4.2)	 − 1.3	0.19	
Lymphocyte subtype analysis	
 CD3+ T cells/lymphocyte (%)	96.7(89.1, 97.7)	96.5(94.6, 97.7)	-0.68	0.49	
 CD4+ T cells/lymphocyte (%)	29.3 ± 14.3	33.4 ± 20.5	0.39	0.69	
 CD8+ T cells/lymphocyte (%)	59.3 ± 17.3	58.3 ± 22.8	0.04	0.97	
 Ratio of CD4+/CD8+ T cell	0.4(0.3, 0.98)	0.55(0.2, 1.3)	-0.37	0.71	

Serum cytokine analysis

There were 28 patients who underwent serum cytokine analysis at the time of diagnosis of CIP, including interleukin (IL)-6, IL-8, IL-10 and tumor necrosis factor (TNF)-α (Fig. 4). The serum concentrations of IL-6, IL-8, IL-10 and TNF-α were 21.7 ± 19.1 pg/ml (range: 2–77 pg/ml; normal reference range: < 5.9 pg/ml; 21 patients/75% with elevated serum IL-6), 28.1 ± 22.6 pg/ml (range: 7–98 pg/ml; normal reference range: < 62 pg/ml; 2 patients/7.1% with elevated serum IL-8), 9.1 ± 10.8 pg/ml (range: 5–51.9 pg/ml; normal reference range: < 9.1 pg/ml; 5 patients/17.9% with elevated serum IL-10), and 14.8 ± 14.9 pg/ml (range: 3–63.9 pg/ml; normal reference range: < 8.1 pg/ml; 19 patients/67.9% with elevated serum TNF-α).Fig. 4 The serum cytokine analysis results of checkpoint inhibitor pneumonitis (CIP) patients. The normal reference ranges for IL-6, IL-8, IL-10 and TNF-α were < 5.9 pg/ml, < 62 pg/ml, < 9.1 pg/ml, and < 8.1 pg/ml, respectively

Discussion

The percentage of lymphocytes in the BALF was usually less than 15% in healthy individuals (8.4% in nonsmoker-healthy individuals and 3.8% in smoker-healthy individuals) [17, 18]. A BALF lymphocyte percentage greater than 15% was defined as a lymphocytic cellular pattern [17]. A lymphocyte percentage ≥ 25% was considered to indicate pulmonary granulomatous diseases, drug-related ILD, cryptogenic OP, NSIP or hypersensitivity pneumonitis (HP) [17]. Suresh et al. compared the BALF features of patients who were prescribed anticancer ICI therapy. The characteristics of the BALF ﻿differential cell count in patients without CIP after ICI administration were similar to those of healthy controls. However, the lymphocyte percentage in BALF increases as patients suffer from CIPs [9, 19]. In our cohort, the percentage of BALF lymphocytes was 36.7 ± 22.5%, and 34 CIP patients (81%) exhibited a lymphocytic cellular pattern.

Meyer et al. conducted a study to characterize the BALF T lymphocyte subset in clinically healthy volunteers in two different age groups (19–36) years (younger group) versus. 64–83 years (older group). The percentage of lymphocytes in the BALF fluid in the older group was greater than that in the younger group [17% vs. 8.3%, P < 0.05; 95% CI (2.7–14.7)]. The BALF CD3+CD4+/CD3 + CD8 + cell ratio was greater in the older group than in the younger group [(7.6 ± 1.5) vs. (1.9 ± 0.2), P < 0.001] [20]. There was no established normal reference range of BALF CD3+CD4+% or CD3+CD8+% for healthy individuals, and there were no special clinical indications for testing for BALF CD3+CD4+% and/or CD3+CD8+%. However, the BALF CD3+CD4+/CD3+CD8+ ratio seems to be correlated with several special ILDs, especially for pulmonary granulomatous diseases. The average percentages of BALF CD3+CD4+/CD3+CD8+ cells were 1.5 for smokers-healthy patients and 2.6 for nonsmokers-healthy patients [18]. For patients with ILDs, the presence of a BALF lymphocytic cellular pattern with an inverted (< 1.0) CD3+CD4+/CD3+CD8 + ratio could be a diagnostic indicator for HP. The BALF CD3+CD4+/CD3+CD8+ ratio in the HP ranged from 0.5 to 1.5 [18]. For most pulmonary sarcoidosis patients, BALF cell count differentials also exhibited a lymphocytic cellular pattern; however, BALF lymphocyte subset analysis revealed a high CD3+CD4+/CD3+CD8+ ratio. A BALF CD3+CD4+/CD3+CD8+ ratio ≥ 4 was strongly correlated with sarcoidosis and might be a diagnostic indicator for ILD patients with a BALF lymphocytic cellular pattern [17, 21, 22].

Suresh et al. [9] performed flow cytometry analysis of BALF from patients with CIP. In their study, both the BALF CD3+CD4+ and CD3+CD8+ T-cell percentages were approximately 10% of live cells. PD-1/PD-L1 inhibitors facilitate the activation of cytotoxic T cells against tumor cells [23, 24]. CD8+ T cells are the effectors of ICI antitumor effects and are associated with varied levels and states of CD8+ T-cell infiltration in tumors before and during ICI therapy [25]. Although the pathogenesis of CIP has not been identified until recently, it seems to be related to the dysregulated activation of T cells, especially CD8+ T cells, in the lung. In Suzuki’s CIP cohort, the percentage of BALF lymphocytes was 34.8% (7.5%-75%), and the ratio of BALF CD4+/CD8+ T-cell was 1.05 (0.07–4.33) [10]. Pulmonary tissues obtained from CIP and non-CIP NSCLC patients after ICI therapy by surgical biopsy were analyzed by Lin’s method: the number of CD8+ T cells was increased, while the number of resting CD4+ T cells was decreased in the CIP group [26]. Hone Lopez et al. performed immunohistochemical analysis of colon biopsies from patients with checkpoint inhibitor-induced colitis [7]. There was heavy mucosal infiltration of CD8+ T cells in the affected colon, both in the deep and superficial colon mucosa. CD8+ T cells also play a role in ICI-related Stevens-Johnson syndrome, toxic epidermal necrosis and vitiligo [27]. In our cohort, the BALF differential cell count also indicated lymphocytosis. Noteworthily, the median ratio of BALF CD3+CD4+/CD3+CD8+ lymphocytes was 0.5 (0.3, 1.0) in our study, which indicated a CD8+-dominant T cell inflammation. Suzuki et al. [10] also found that the proportion of BALF PD-1+ PD-L1+CD8+ T cells was correlated with the CTCAE grade of CIPs. However, there was no significant difference in the BALF T cell subset analysis between the high-grade and low-grade CIP groups in our study.

Serum proinflammatory cytokine levels were elevated in patients with irAEs, especially in those with severe irAEs. Elevated circulating and/or pulmonary inflammatory cytokines were reported in patients with CIP [19, 28]. IL-6 is an essential cytokine for the generation of Th17 cells from naïve CD4 + T cells [29], contributing to the development of several inflammatory/autoimmune diseases [30]. IL-6 is also a prognostic factor with higher serum levels associated with shorter overall survival in patients with metastatic melanoma receiving ICI in large randomized trials [31]. Serum levels of IL-6 at baseline and changes after immunotherapy might also have a prognostic significance in patients with advanced cutaneous squamous cell carcinoma [32]. It has been suggested that chronic inflammation and IL-6 cytokine signaling are involved in resistance to immunotherapy [33]. Targeting IL-6 could be an effective approach to treat irAEs without hindering antitumor immunity [34]. Compared with healthy controls, the BALF IL-6 concentration was elevated in patients with CIP; however, the serum IL-6 concentration was not elevated in Kowalski’s study [19]. Compared with those at baseline, both the serum and BALF IL-17A and IL-35 levels were elevated in patients with non-small cell lung cancer when they were suffering from CIP [28]. The level of BALF IFN-γ-induced protein 10 (IP-10) was elevated, and the level of IL-2 was decreased in patients with CIP compared with patients with pulmonary infection or lung cancer [35]. Given that inflammatory cytokines are not routinely tested in clinical practice, we could only analyze the serum inflammatory cytokine profiles of patients with CIPs. It was shown that the serum IL-6 concentration was significantly elevated in cancer patients who were suffering from CIPs. Tocilizumab, siltuximab, and JAK inhibitors are effective anti-IL-6 medications. Tocilizumab was suggested for severe irAEs in clinical practice [30]. JAK inhibitors were reported to be effective at treating fulminant myocarditis or steroid-resistant ICI-related acute transverse myelitis [4, 36]. Because T-cell activation is one of the potential pathogeneses of CIPs and because JAK inhibitors can effectively reduce T-cell activation [37], JAK inhibitors were assumed to effectively ameliorate severe CIPs.

This study has several limitations. First, not all CIP patients underwent BAL when they were suffering from CIPs, which might influence the exploration of differences between high-grade and low-grade CIPs because of the small sample size. Second, lung biopsies were not performed simultaneously with BAL fluid. Immunohistochemical analysis and/or single-cell sequencing of pulmonary tissues might be useful for identifying the key effector cells involved in CIPs. Third, there was no further exploration of the different states or subtypes of CD8+ T cells in our retrospective study. Fourth, as in most studies, there was no BALF T-cell subset analysis result for patients without CIPs who were administered anticancer ICI therapy, because it was not a routine test for these patients. We had no idea about the T-cell landscape for them. These patients should be included in our future well-designed prospective studies.

Conclusions

The CD3+CD8+ lymphocytosis pattern was the main inflammatory profile in the BALF of the CIP patients in our cohort. However, there was no significant difference in BALF features between patients with low-grade CIPs and those with high-grade CIPs. Targeting CD3+CD8+ lymphocytes might be a treatment option for CIPs.

Author contribution

Ruxuan Chen Conceptualization, Data curation, Formal analysis, Writing—original draft, Visualization. Yujie Shi Conceptualization, Data curation, Formal analysis, Writing—original draft, Visualization. Nan Fang Conceptualization, Formal analysis, Validation, Writing—original draft, Visualization. Chi Shao Investigation, Validation, Writing—review and editing. Hui Huang Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing—review and editing. Ruili Pan Investigation, Validation, Writing—review and editing. Yan Xu Resources, Investigation, Validation, Writing—review and editing. Mengqi Wang Investigation, Validation, Writing—original draft. Xiangning Liu Investigation, Validation, Writing—original draft. Kai Xu Investigation, Validation, Writing—review and editing. Rui Zhu Investigation, Validation, Writing—review and editing. Mengzhao Wang Funding acquisition, Resources, Supervision, Writing—review and editing.

Funding

This work was supported by the National High Level Hospital Clinical Research Funding (grant numbers 2022-PUMCH-C-069, 2022-PUMCH-C-054, and 2022-PUMCH-A-009).

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

This study was approved by the institutional ethical review board (IRB) of Peking Union Medical College Hospital (approval number: K3445) in accordance with the Declaration of Helsinki. Written informed consent from each patient was waived because our study was conducted using anonymized health care data, which met the IRB’s minimal risk waiver criteria.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ruxuan Chen, Yujie Shi and Nan Fang have contributed equally to this work.
==== Refs
References

1. Postow MA Sidlow R Hellmann MD Immune-related adverse events associated with immune checkpoint blockade N Engl J Med 2018 378 2 158 168 10.1056/NEJMra1703481 29320654
Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158–168. 10.1056/NEJMra170348129320654 10.1056/NEJMra1703481
2. Ramos-Casals M Brahmer JR Callahan MK Flores-Chavez A Keegan N Khamashta MA Lambotte O Mariette X Prat A Suarez-Almazor ME Immune-related adverse events of checkpoint inhibitors Nat Rev Dis Primers 2020 6 1 38 10.1038/s41572-020-0160-6 32382051
Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chavez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suarez-Almazor ME (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6(1):38. 10.1038/s41572-020-0160-632382051 10.1038/s41572-020-0160-6
3. Rashdan S Minna JD Gerber DE Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy Lancet Respir Med 2018 6 6 472 478 10.1016/S2213-2600(18)30172-3 29856320
Rashdan S, Minna JD, Gerber DE (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6(6):472–478. 10.1016/S2213-2600(18)30172-329856320 10.1016/S2213-2600(18)30172-3
4. Nguyen LS Bretagne M Arrondeau J Zahr N Ederhy S Abbar B Pinna B Allenbach Y Mira JP Moslehi J Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept J Immunother Cancer 2022 10 4 e004699 10.1136/jitc-2022-004699 35383117
Nguyen LS, Bretagne M, Arrondeau J, Zahr N, Ederhy S, Abbar B, Pinna B, Allenbach Y, Mira JP, Moslehi J et al (2022) Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. J Immunother Cancer 10(4):e004699. 10.1136/jitc-2022-00469935383117 10.1136/jitc-2022-004699
5. Bukhari S Henick BS Winchester RJ Lerrer S Adam K Gartshteyn Y Maniar R Lin Z Khodadadi-Jamayran A Tsirigos A Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors Cell Rep Med 2023 4 1 100868 10.1016/j.xcrm.2022.100868 36513074
Bukhari S, Henick BS, Winchester RJ, Lerrer S, Adam K, Gartshteyn Y, Maniar R, Lin Z, Khodadadi-Jamayran A, Tsirigos A et al (2023) Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Rep Med 4(1):100868. 10.1016/j.xcrm.2022.10086836513074 10.1016/j.xcrm.2022.100868
6. Takahashi Y Nagaya T Iwaya Y Okamura T Hirayama A Iwaya M Uehara T Umemura T CD8(+) lymphocyte infiltration is a specific feature of colitis induced by immune checkpoint inhibitors Dig Dis Sci 2023 68 2 451 459 10.1007/s10620-022-07598-2 35748996
Takahashi Y, Nagaya T, Iwaya Y, Okamura T, Hirayama A, Iwaya M, Uehara T, Umemura T (2023) CD8(+) lymphocyte infiltration is a specific feature of colitis induced by immune checkpoint inhibitors. Dig Dis Sci 68(2):451–459. 10.1007/s10620-022-07598-235748996 10.1007/s10620-022-07598-2
7. Hone Lopez S Kats-Ugurlu G Renken RJ Buikema HJ de Groot MR Visschedijk MC Dijkstra G Jalving M de Haan JJ Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis Virchows Arch 2021 479 6 1119 1129 10.1007/s00428-021-03170-x 34338882
Hone Lopez S, Kats-Ugurlu G, Renken RJ, Buikema HJ, de Groot MR, Visschedijk MC, Dijkstra G, Jalving M, de Haan JJ (2021) Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis. Virchows Arch 479(6):1119–1129. 10.1007/s00428-021-03170-x34338882 10.1007/s00428-021-03170-x
8. Dougan M Weighing antitumor immunity against life-threatening myocarditis from immune-checkpoint inhibitors Cancer Discov 2023 13 5 1040 1042 10.1158/2159-8290.CD-23-0199 37139724
Dougan M (2023) Weighing antitumor immunity against life-threatening myocarditis from immune-checkpoint inhibitors. Cancer Discov 13(5):1040–1042. 10.1158/2159-8290.CD-23-019937139724 10.1158/2159-8290.CD-23-0199
9. Suresh K Naidoo J Zhong Q Xiong Y Mammen J de Flores MV Cappelli L Balaji A Palmer T Forde PM The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis J Clin Investig 2019 129 10 4305 4315 10.1172/JCI128654 31310589
Suresh K, Naidoo J, Zhong Q, Xiong Y, Mammen J, de Flores MV, Cappelli L, Balaji A, Palmer T, Forde PM et al (2019) The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. J Clin Investig 129(10):4305–4315. 10.1172/JCI12865431310589 10.1172/JCI128654
10. Suzuki K Yanagihara T Matsumoto K Kusaba H Yamauchi T Ikematsu Y Tanaka K Otsubo K Inoue H Yoneshima Y Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease Int Immunol 2020 32 8 547 557 10.1093/intimm/dxaa022 32253426
Suzuki K, Yanagihara T, Matsumoto K, Kusaba H, Yamauchi T, Ikematsu Y, Tanaka K, Otsubo K, Inoue H, Yoneshima Y et al (2020) Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. Int Immunol 32(8):547–557. 10.1093/intimm/dxaa02232253426 10.1093/intimm/dxaa022
11. Larsen BT Chae JM Dixit AS Hartman TE Peikert T Roden AC Clinical and histopathologic features of immune checkpoint inhibitor-related pneumonitis Am J Surg Pathol 2019 43 10 1331 1340 10.1097/PAS.0000000000001298 31162288
Larsen BT, Chae JM, Dixit AS, Hartman TE, Peikert T, Roden AC (2019) Clinical and histopathologic features of immune checkpoint inhibitor-related pneumonitis. Am J Surg Pathol 43(10):1331–1340. 10.1097/PAS.000000000000129831162288 10.1097/PAS.0000000000001298
12. Meyer KC Raghu G Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? Eur Respir J 2011 38 4 761 769 10.1183/09031936.00069509 21540304
Meyer KC, Raghu G (2011) Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? Eur Respir J 38(4):761–769. 10.1183/09031936.0006950921540304 10.1183/09031936.00069509
13. Gharsalli H Mlika M Sahnoun I Maalej S Douik El Gharbi L Mezni FE The utility of bronchoalveolar lavage in the evaluation of interstitial lung diseases: a clinicopathological perspective Semin Diagn Pathol 2018 35 5 280 287 10.1053/j.semdp.2018.08.003 30173880
Gharsalli H, Mlika M, Sahnoun I, Maalej S, Douik El Gharbi L, Mezni FE (2018) The utility of bronchoalveolar lavage in the evaluation of interstitial lung diseases: a clinicopathological perspective. Semin Diagn Pathol 35(5):280–287. 10.1053/j.semdp.2018.08.00330173880 10.1053/j.semdp.2018.08.003
14. Sun Y Shao C Li S Xu Y Xu K Zhang Y Huang H Wang M Xu Z Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer Asia Pac J Clin Oncol 2020 16 6 299 304 10.1111/ajco.13380 32757454
Sun Y, Shao C, Li S, Xu Y, Xu K, Zhang Y, Huang H, Wang M, Xu Z (2020) Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer. Asia Pac J Clin Oncol 16(6):299–304. 10.1111/ajco.1338032757454 10.1111/ajco.13380
15. Travis WD Costabel U Hansell DM King TE Jr Lynch DA Nicholson AG Ryerson CJ Ryu JH Selman M Wells AU An official American thoracic society/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias Am J Respir Crit Care Med 2013 188 6 733 748 10.1164/rccm.201308-1483ST 24032382
Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU et al (2013) An official American thoracic society/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188(6):733–748. 10.1164/rccm.201308-1483ST24032382 10.1164/rccm.201308-1483ST
16. National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
17. Meyer KC Raghu G Baughman RP Brown KK Costabel U du Bois RM Drent M Haslam PL Kim DS Nagai S An official American thoracic society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease Am J Respir Crit Care Med 2012 185 9 1004 1014 10.1164/rccm.201202-0320ST 22550210
Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, Drent M, Haslam PL, Kim DS, Nagai S et al (2012) An official American thoracic society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 185(9):1004–1014. 10.1164/rccm.201202-0320ST22550210 10.1164/rccm.201202-0320ST
18. Hogea SP Tudorache E Pescaru C Marc M Oancea C Bronchoalveolar lavage: role in the evaluation of pulmonary interstitial disease Expert Rev Respir Med 2020 14 11 1117 1130 10.1080/17476348.2020.1806063 32847429
Hogea SP, Tudorache E, Pescaru C, Marc M, Oancea C (2020) Bronchoalveolar lavage: role in the evaluation of pulmonary interstitial disease. Expert Rev Respir Med 14(11):1117–1130. 10.1080/17476348.2020.180606332847429 10.1080/17476348.2020.1806063
19. Kowalski B Valaperti A Bezel P Steiner UC Scholtze D Wieser S Vonow-Eisenring M Widmer A Kohler M Franzen D Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study J Cancer Res Clin Oncol 2022 148 7 1711 1720 10.1007/s00432-021-03750-z 34347128
Kowalski B, Valaperti A, Bezel P, Steiner UC, Scholtze D, Wieser S, Vonow-Eisenring M, Widmer A, Kohler M, Franzen D (2022) Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study. J Cancer Res Clin Oncol 148(7):1711–1720. 10.1007/s00432-021-03750-z34347128 10.1007/s00432-021-03750-z
20. Meyer KC Soergel P Variation of bronchoalveolar lymphocyte phenotypes with age in the physiologically normal human lung Thorax 1999 54 8 697 700 10.1136/thx.54.8.697 10413722
Meyer KC, Soergel P (1999) Variation of bronchoalveolar lymphocyte phenotypes with age in the physiologically normal human lung. Thorax 54(8):697–700. 10.1136/thx.54.8.69710413722 10.1136/thx.54.8.697
21. Danila E Norkuniene J Jurgauskiene L Malickaite R Diagnostic role of BAL fluid CD4/CD8 ratio in different radiographic and clinical forms of pulmonary sarcoidosis Clin Respir J 2009 3 4 214 221 10.1111/j.1752-699X.2008.00126.x 20298407
Danila E, Norkuniene J, Jurgauskiene L, Malickaite R (2009) Diagnostic role of BAL fluid CD4/CD8 ratio in different radiographic and clinical forms of pulmonary sarcoidosis. Clin Respir J 3(4):214–221. 10.1111/j.1752-699X.2008.00126.x20298407 10.1111/j.1752-699X.2008.00126.x
22. Reschke R Shapiro JW Yu J Rouhani SJ Olson DJ Zha Y Gajewski TF Checkpoint blockade-induced dermatitis and colitis are dominated by tissue-resident memory T Cells and Th1/Tc1 cytokines Cancer Immunol Res 2022 10 10 1167 1174 10.1158/2326-6066.CIR-22-0362 35977003
Reschke R, Shapiro JW, Yu J, Rouhani SJ, Olson DJ, Zha Y, Gajewski TF (2022) Checkpoint blockade-induced dermatitis and colitis are dominated by tissue-resident memory T Cells and Th1/Tc1 cytokines. Cancer Immunol Res 10(10):1167–1174. 10.1158/2326-6066.CIR-22-036235977003 10.1158/2326-6066.CIR-22-0362
23. Assarzadegan N Montgomery E Anders RA Immune checkpoint inhibitor colitis: the flip side of the wonder drugs Virchows Arch 2018 472 1 125 133 10.1007/s00428-017-2267-z 29143108
Assarzadegan N, Montgomery E, Anders RA (2018) Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch 472(1):125–133. 10.1007/s00428-017-2267-z29143108 10.1007/s00428-017-2267-z
24. Pardoll DM The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 2012 12 4 252 264 10.1038/nrc3239 22437870
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. 10.1038/nrc323922437870 10.1038/nrc3239
25. Sade-Feldman M Yizhak K Bjorgaard SL Ray JP de Boer CG Jenkins RW Lieb DJ Chen JH Frederick DT Barzily-Rokni M Defining T cell states associated with response to checkpoint immunotherapy in melanoma Cell 2018 175 4 998 1013 e1020 10.1016/j.cell.2018.10.038 30388456
Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M et al (2018) Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175(4):998-1013 e1020. 10.1016/j.cell.2018.10.03830388456 10.1016/j.cell.2018.10.038
26. Lin X Deng J Deng H Yang Y Sun N Zhou M Qin Y Xie X Li S Zhong N Comprehensive analysis of the immune microenvironment in checkpoint inhibitor pneumonitis Front Immunol 2021 12 818492 10.3389/fimmu.2021.818492 35095920
Lin X, Deng J, Deng H, Yang Y, Sun N, Zhou M, Qin Y, Xie X, Li S, Zhong N et al (2021) Comprehensive analysis of the immune microenvironment in checkpoint inhibitor pneumonitis. Front Immunol 12:818492. 10.3389/fimmu.2021.81849235095920 10.3389/fimmu.2021.818492
27. Williams KC Gault A Anderson AE Stewart CJ Lamb CA Speight RA Rajan N Plummer R Pratt AG Immune-related adverse events in checkpoint blockade: observations from human tissue and therapeutic considerations Front Immunol 2023 14 1122430 10.3389/fimmu.2023.1122430 36776862
Williams KC, Gault A, Anderson AE, Stewart CJ, Lamb CA, Speight RA, Rajan N, Plummer R, Pratt AG (2023) Immune-related adverse events in checkpoint blockade: observations from human tissue and therapeutic considerations. Front Immunol 14:1122430. 10.3389/fimmu.2023.112243036776862 10.3389/fimmu.2023.1122430
28. Wang YN Lou DF Li DY Jiang W Dong JY Gao W Chen HC Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer Oncol Lett 2020 20 1 611 622 10.3892/ol.2020.11618 32565986
Wang YN, Lou DF, Li DY, Jiang W, Dong JY, Gao W, Chen HC (2020) Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Oncol Lett 20(1):611–622. 10.3892/ol.2020.1161832565986 10.3892/ol.2020.11618
29. Kimura A Kishimoto T IL-6: regulator of Treg/Th17 balance Eur J Immunol 2010 40 7 1830 1835 10.1002/eji.201040391 20583029
Kimura A, Kishimoto T (2010) IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40(7):1830–1835. 10.1002/eji.20104039120583029 10.1002/eji.201040391
30. Kishimoto T Kang S IL-6 Revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19 Annu Rev Immunol 2022 40 323 348 10.1146/annurev-immunol-101220-023458 35113729
Kishimoto T, Kang S (2022) IL-6 Revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19. Annu Rev Immunol 40:323–348. 10.1146/annurev-immunol-101220-02345835113729 10.1146/annurev-immunol-101220-023458
31. Laino AS Woods D Vassallo M Qian X Tang H Wind-Rotolo M Weber J Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition J Immunother Cancer 2020 8 1 e000842 10.1136/jitc-2020-000842 32581042
Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, Weber J (2020) Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer 8(1):e000842. 10.1136/jitc-2020-00084232581042 10.1136/jitc-2020-000842
32. Mallardo D Simeone E Festino L Tuffanelli M Vanella V Trojaniello C Vitale MG Ottaviano M Capone M Madonna G IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab J Transl Med 2023 21 1 140 10.1186/s12967-023-03971-5 36823670
Mallardo D, Simeone E, Festino L, Tuffanelli M, Vanella V, Trojaniello C, Vitale MG, Ottaviano M, Capone M, Madonna G et al (2023) IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab. J Transl Med 21(1):140. 10.1186/s12967-023-03971-536823670 10.1186/s12967-023-03971-5
33. Soler MF Abaurrea A Azcoaga P Araujo AM Caffarel MM New perspectives in cancer immunotherapy: targeting IL-6 cytokine family J Immunother Cancer 2023 11 11 e007530 10.1136/jitc-2023-007530 37945321
Soler MF, Abaurrea A, Azcoaga P, Araujo AM, Caffarel MM (2023) New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. J Immunother Cancer 11(11):e007530. 10.1136/jitc-2023-00753037945321 10.1136/jitc-2023-007530
34. Fa'ak F Buni M Falohun A Lu H Song J Johnson DH Zobniw CM Trinh VA Awiwi MO Tahon NH Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events J Immunother Cancer 2023 11 6 e006814 10.1136/jitc-2023-006814 37328287
Fa’ak F, Buni M, Falohun A, Lu H, Song J, Johnson DH, Zobniw CM, Trinh VA, Awiwi MO, Tahon NH et al (2023) Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer 11(6):e006814. 10.1136/jitc-2023-00681437328287 10.1136/jitc-2023-006814
35. Si X Zheng X Tian X Wang H Xu Y Zhao J Chen M Zhong W Wang M Zhang L Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: a case-control study Thorac Cancer 2023 14 21 2038 2044 10.1111/1759-7714.14987 37259819
Si X, Zheng X, Tian X, Wang H, Xu Y, Zhao J, Chen M, Zhong W, Wang M, Zhang L et al (2023) Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: a case-control study. Thorac Cancer 14(21):2038–2044. 10.1111/1759-7714.1498737259819 10.1111/1759-7714.14987
36. Picca A Valyraki N Birzu C Kramkimel N Hermine O Zahr N Berzero G Psimaras D Anti-interleukin-6 and Janus kinase inhibitors for severe neurologic toxicity of checkpoint inhibitors Neurol Neuroimmunol Neuroinflamm 2021 10.1212/NXI.0000000000001073 34497101
Picca A, Valyraki N, Birzu C, Kramkimel N, Hermine O, Zahr N, Berzero G, Psimaras D (2021) Anti-interleukin-6 and Janus kinase inhibitors for severe neurologic toxicity of checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. 10.1212/NXI.000000000000107334497101 10.1212/NXI.0000000000001073
37. Tanaka Y Luo Y O'Shea JJ Nakayamada S Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach Nat Rev Rheumatol 2022 18 3 133 145 10.1038/s41584-021-00726-8 34987201
Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S (2022) Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 18(3):133–145. 10.1038/s41584-021-00726-834987201 10.1038/s41584-021-00726-8
